{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:51:19Z","timestamp":1791049879621,"version":"4.1.0"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2967\/jnumed.122.264489","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T21:15:20Z","timestamp":1666905320000},"page":"605-610","source":"Crossref","is-referenced-by-count":31,"title":["Prognostic Value of Tumor Volume Assessment on PSMA PET After<sup>177<\/sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET\/CT Consensus Statement and RECIP 1.0"],"prefix":"10.2967","volume":"64","author":[{"given":"Felix","family":"Kind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula A.","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2023040307200706000_64.4.605.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2023040307200706000_64.4.605.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014"},{"key":"2023040307200706000_64.4.605.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023040307200706000_64.4.605.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023040307200706000_64.4.605.5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023040307200706000_64.4.605.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023040307200706000_64.4.605.7","unstructured":"FDA approves Pluvicto for metastatic castration-resistant prostate cancer. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Updated March 23, 2022. Accessed November 29, 2022."},{"key":"2023040307200706000_64.4.605.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2023040307200706000_64.4.605.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260836"},{"key":"2023040307200706000_64.4.605.10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.605.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2023040307200706000_64.4.605.12","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.605.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193581"},{"key":"2023040307200706000_64.4.605.14","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","article-title":"68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer","volume":"45","author":"Schmidkonz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.605.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2023040307200706000_64.4.605.16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/a-1035-9052","article-title":"Determination of whole-body tumour burden on [68Ga]PSMA-11 PET\/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy","volume":"58","author":"Michalski","year":"2019","journal-title":"Nuklearmedizin."},{"key":"2023040307200706000_64.4.605.17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.119.236075","article-title":"Repeatability of quantitative 18F-DCFPyL PET\/CT measurements in metastatic prostate cancer","volume":"61","author":"Jansen","year":"2020","journal-title":"J Nucl Med."},{"key":"2023040307200706000_64.4.605.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3573-4"},{"key":"2023040307200706000_64.4.605.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2023040307200706000_64.4.605.20","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.605.21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0037-1616480","article-title":"177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer [in German]","volume":"55","author":"Fendler","year":"2016","journal-title":"Nuklearmedizin."},{"key":"2023040307200706000_64.4.605.22","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.605.23","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"2023040307200706000_64.4.605.24","first-page":"194","article-title":"Beth Israel plugin for FIJI: free and open source software for scientific research [in French]","volume":"40","author":"Kanoun","year":"2016","journal-title":"Med Nucl (Paris)."},{"key":"2023040307200706000_64.4.605.25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10985-015-9330-3","article-title":"Estimating the concordance probability in a survival analysis with a discrete number of risk groups","volume":"22","author":"Heller","year":"2016","journal-title":"Lifetime Data Anal."},{"key":"2023040307200706000_64.4.605.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2023040307200706000_64.4.605.27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging."},{"key":"2023040307200706000_64.4.605.28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:20:35Z","timestamp":1680531635000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2967\/jnumed.122.264489"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264489","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}